These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 1324649

  • 21. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
    Kenny MT, Dulworth JK, Brackman MA.
    Diagn Microbiol Infect Dis; 1991; 14(1):29-31. PubMed ID: 1826479
    [Abstract] [Full Text] [Related]

  • 22. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.
    Sahm DF, Kissinger J, Gilmore MS, Murray PR, Mulder R, Solliday J, Clarke B.
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1588-91. PubMed ID: 2554802
    [Abstract] [Full Text] [Related]

  • 23. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
    Itokazu GS, Nathan C, Hariharan R, Kostman JR, Kabins SA, Weinstein RA.
    Chemotherapy; 1996 Sep; 42(4):235-9. PubMed ID: 8804789
    [Abstract] [Full Text] [Related]

  • 24. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.
    Mobarakai N, Quale JM, Landman D.
    Antimicrob Agents Chemother; 1994 Feb; 38(2):385-7. PubMed ID: 8192473
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE, Smith JR, Raut A, Rybak MJ.
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [Abstract] [Full Text] [Related]

  • 26. In vitro susceptibility of gram-positive cocci to paldimycin.
    Pohlod DJ, Saravolatz LD, Somerville MM.
    Antimicrob Agents Chemother; 1987 Jan; 31(1):104-7. PubMed ID: 3105438
    [Abstract] [Full Text] [Related]

  • 27. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E, Morosini MI, Pascual A, Tubau F, Alcalá J, Liñares J, Hernández-Bello JR, Baquero F, Perea E, Martín R, Jones RN, Cantón R, SENTRY Surveillance Program, Spain (2002-2006).
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [Abstract] [Full Text] [Related]

  • 28. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE.
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [Abstract] [Full Text] [Related]

  • 29. Comparison of in vitro activity of daptomycin, vancomycin and fluoroquinolones in broth and serum against Staphylococcus epidermidis as determined by time-kill kinetics.
    Lentino JR, Strodthman R.
    Chemotherapy; 1989 Apr; 35(3):168-73. PubMed ID: 2548817
    [Abstract] [Full Text] [Related]

  • 30. In vitro activity of SK&F 104662, a new glycopeptide antibiotic.
    Yao JD, Eliopoulos GM, Moellering RC.
    Antimicrob Agents Chemother; 1989 Jun; 33(6):965-7. PubMed ID: 2548444
    [Abstract] [Full Text] [Related]

  • 31. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.
    J Antimicrob Chemother; 2018 Oct 01; 73(10):2748-2756. PubMed ID: 29982565
    [Abstract] [Full Text] [Related]

  • 32. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE.
    Antimicrob Agents Chemother; 1997 Oct 01; 41(10):2165-72. PubMed ID: 9333042
    [Abstract] [Full Text] [Related]

  • 33. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE, Tenover FC.
    Microb Drug Resist; 2003 Oct 01; 9(4):389-93. PubMed ID: 15000746
    [Abstract] [Full Text] [Related]

  • 34. In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.
    Rolston KV, Nguyen H, Messer M.
    Antimicrob Agents Chemother; 1990 Nov 01; 34(11):2137-41. PubMed ID: 2149921
    [Abstract] [Full Text] [Related]

  • 35. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I.
    Int J Antimicrob Agents; 2007 Mar 01; 29(3):322-5. PubMed ID: 17204403
    [Abstract] [Full Text] [Related]

  • 36. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Moeck G.
    J Antimicrob Chemother; 2009 Jun 01; 63(6):1191-9. PubMed ID: 19369269
    [Abstract] [Full Text] [Related]

  • 37. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
    King A, Phillips I.
    J Antimicrob Chemother; 2001 Aug 01; 48(2):219-23. PubMed ID: 11481291
    [Abstract] [Full Text] [Related]

  • 38. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC, Ribou G, Masquelier B.
    Pathol Biol (Paris); 1992 May 01; 40(5):461-5. PubMed ID: 1386667
    [Abstract] [Full Text] [Related]

  • 39. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
    Biavasco F, Manso E, Varaldo PE.
    Antimicrob Agents Chemother; 1991 Jan 01; 35(1):195-7. PubMed ID: 1826593
    [Abstract] [Full Text] [Related]

  • 40. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
    Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ.
    Antimicrob Agents Chemother; 2003 Jul 01; 47(7):2334-8. PubMed ID: 12821492
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.